| Detected | Trial | Change |
|---|---|---|
| 2026-08-13 | NCT05308901 Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… |
critical Trial terminated |
| 2026-08-13 | NCT05308901 Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… |
critical Trial terminated: PI opted to close study due to poor accrual. |
| 2026-08-13 | NCT05308901 Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… |
date change Completion moved earlier: 2027-06 -> 2025-08-11 |
| 2026-07-24 | NCT07614048 Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells… |
overall status: Temporarily Not Available → Available |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06175000 | Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who… | Primary Central Nervous System Lymphoma | Recruiting |
| NCT06353997 | Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | Triple Negative Breast Cancer | Recruiting |
| NCT05913388 | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic… | Metastatic Melanoma | Recruiting |
| NCT04938609 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | Head and Neck Cancer | Active, Not Recruiting |
| NCT02688712 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | Rectal Adenocarcinoma | Active, Not Recruiting |
| NCT03650894 | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative… | Breast Neoplasm Female | Active, Not Recruiting |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With… | BRAF NP_004324.2:p.V600M | Active, Not Recruiting |
| NCT01416831 | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With… | Metastatic Melanoma | Active, Not Recruiting |
| NCT04373031 | Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer | Breast Cancer | Active, Not Recruiting |
| NCT02306954 | Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in… | Renal Cell Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT02422381 | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | Carcinoma, Non-Small-Cell Lung | Active, Not Recruiting |
| NCT02734290 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | Triple Negative Breast Cancer | Active, Not Recruiting |
| NCT03247712 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | Head and Neck Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT04470024 | Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With… | Cancer of the Head and Neck | Recruiting |
| NCT06719362 | A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01… | Advanced Solid Tumors | Recruiting |
| NCT04520711 | Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor… | Malignant Epithelial Neoplasms | Active, Not Recruiting |
| NCT04895761 | Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in… | Breast Cancer | Active, Not Recruiting |
| NCT05249114 | Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive… | Neuroendocrine Tumors | Active, Not Recruiting |
| NCT02812524 | Ipilimumab for Head and Neck Cancer Patients | Squamous Cell Carcinoma of the Head and Neck | Active, Not Recruiting |
| NCT05349890 | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T… | Malignant Epithelial Neoplasms | Active, Not Recruiting |
| NCT07620496 | CAN1012 in Pre-malignant Oral Dysplasia | Oral Epithelial Dysplasia (OED) | Not Yet Recruiting |
| NCT07408856 | CAN1012 in Pre-Malignant DCIS and LCIS | Ductal Carcinoma in Situ | Not Yet Recruiting |
| Not specified | |||
| NCT05508984 | Clinical Outcomes and Patient Satisfaction With Use of the Amma System | Breast Cancer | Active, Not Recruiting |